Test gel QTORIN for adults with pachyonychia congenita
Part of Genetic & congenital, Skin clinical trials.
This Phase 3 study tests the safety and how the body absorbs (pharmacokinetics) of a rapamycin gel called QTORIN 3.9% in adults with pachyonychia congenita. It may help determine whether this gel is safe and works for people with this rare skin nail condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You completed the earlier PALV-05 (VAPAUS) study
- You can and will use birth control as required by the study
- You are not pregnant and not breastfeeding
- You do not use sirolimus or any sirolimus-type medicine (including creams or gels)
- You do not have other serious medical problems that could interfere with safety or results
- You have not had—or do not plan—procedures or treatments that the study doctor thinks could affect safety or the measurements
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral medication called erlotinib (an EGFR inhibitor) to see if it can reduce the skin symptoms of keratinopathies like epidermolytic ichthyosis, epidermolytic palmoplantar keratoderma, and pachyonychia congenita. The goal is to improve skin condition and quality of life.
This trial tests a topical gel (a cream you apply to skin) containing sirolimus to treat angiokeratomas, which are small growths on the skin. The goal is to see if this treatment is safe and effective.
This Phase 2 study tests ruxolitinib to see if it safely helps regrow hair in people whose alopecia areata is linked to APECED (a rare immune condition). You may qualify if you have significant scalp hair loss for at least 6 months and haven’t had regrowth with other treatments.
This trial tests a new study drug (ZP9830) to see if it is safe and works well for people with plaque psoriasis. You would receive the treatment for 8 weeks, and the study will check how your skin responds.
This trial tests an experimental oral medication called TQH3906 for people with active psoriatic arthritis (PsA), a condition that causes joint pain, swelling, and skin psoriasis. The study aims to see if TQH3906 is safe and effective in reducing arthritis symptoms.
This trial tests an oral medication called TQH3906 for people with moderate to severe plaque psoriasis. It aims to see if the drug can improve skin symptoms and is for adults who have not had enough success with other treatments.
Hear when a new Pachyonychia Congenita trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.